Coronavirus has definitively changed health care delivery and the perceptions of health technologies and digital ecosystems. Industry will need to adjust to the aftermath of COVID-19, take opportunities and learn lessons from 2020 or 2021 could be every inch as challenging.
Before the first wave of the pandemic had tailed off and the second wave fears were not yet borne out, MassMutual Ventures’ Ryan Collins expressed a regret: he wished that that his Asia-focused venture capital firm had done more deals going into 2020, before the coronavirus first slowed business, and then changed the way it had to be done.
Collins, a partner at the Singapore-based branch of MMV, was addressing an In Vivo-hosted panel at the APACMed annual conference,...
Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.
J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.
Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success.
